Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Explore the FGF21 analog and receptor agonist pipeline in MASH, dyslipidemia, and metabolic syndrome — from Fc-fusions to bispecific agonists and mRNA therapeutics.
Article | Rapport Ionic liquid electrolytes are reshaping battery safety and post-lithium chemistries. Explore the 2026 technology landscape: key clusters, geographies, and emerging IP opportunities.
Article | Rapport How carbon nanotube interconnects extend BEOL conductivity beyond copper scaling limits — covering CNT bundles, MWCNT vias, Cu-CNT composites, and CMOS integration.
Article | Rapport Explore novel antifungals, triterpenoid inhibitors, and combination approaches in the invasive fungal infection drug pipeline—covering IFI targets, clinical signals, and emerging therapies.
Article | Rapport Laser additive repair in 2026: patent landscape, key assignees, process clusters, and emerging directions across aerospace, automotive, and defense sectors.
Article | Rapport How do flip-chip and wire bond interconnects differ in thermal cycling reliability for automotive-grade packages? A deep-dive into failure mechanisms, fatigue life, and mitigation strategies.
Article | Rapport How do GaN and SiC devices achieve sub-1ns switching without parasitic ringing? Explore gate driver strategies, PCB layout, monolithic integration, and ZOS.
Article | Rapport Explore the C. difficile drug pipeline: microbiome restoration, toxin neutralization, and recurrence prevention strategies from FMT to monoclonal antibodies.
Article | Rapport Map the 2026 microfluidic fuel cell innovation landscape: four sub-domains, key assignees, power density benchmarks, and five emerging R&D directions.
Article | Rapport How do engineers achieve sub-1ns switching in GaN and SiC devices without parasitic ringing? Explore gate driver strategies, PCB layout, and ZOS from 30+ patents.
Article | Rapport Explore the SPS drug pipeline: GAD65 autoantibodies, GABA pharmacology, rituximab, IVIG, and emerging immunotherapy approaches for this ultra-rare CNS disorder.
Article | Rapport EWoD display technology patent landscape 2026: key assignees, driving waveform innovations, color architectures, and strategic IP gaps across 30+ records.
Article | Rapport How heterogeneous integration of III-V compound semiconductors on silicon enables next-generation RF front-end modules for 5G and beyond. Patent analysis & key players.
Article | Rapport A 2026 patent and literature landscape of cryogenic propellant storage: LH2, LOX, LNG systems, TVS, MLI insulation, and Mars ISRU — key trends and assignees mapped.
Article | Rapport Explore the CF drug pipeline beyond CFTR modulators: SPM therapy, ENaC inhibition, mRNA delivery, gene therapy, and mutation-agnostic approaches for the 10–19% ineligible population.